You can’t ignore the body’s warnings. Early screening will make gastric cancer nowhere to escape!

Zhang Xiaodong

Director of the VIP Department of Digestive Tract Tumors, Peking University School of Clinical Oncology and Beijing Cancer Hospital, chief physician, mainly engaged in chemotherapy and comprehensive treatment of digestive tract tumors, responsible for and participated in the completion of a number of national multi-center clinical studies and international multi-center clinical studies. He has published dozens of papers in domestic and international core journals. He is currently the chairman of the Esophageal Cancer Committee of the Beijing Anti-Cancer Association; the vice chairman of the Tumor Prevention and Treatment Science Popularization Committee of the Chinese Anti-Cancer Association; the vice chairman of the Early Cancer Screening Committee of the Beijing Anti-Cancer Association

Professional expertise

⑴ Oncology Internal Medicine Chemotherapy of digestive tract tumors, mainly including internal medicine chemotherapy of stomach, intestine, esophagus, liver, gallbladder and pancreatic tumors.

⑵Research direction: Chemotherapy of digestive tract tumors and early diagnosis and treatment of recurrence and metastasis, especially chemotherapy and adjuvant chemotherapy of advanced esophageal cancer, gastric cancer, cardiac cancer, colorectal cancer, pancreatic and bile duct cancer; molecular biology research on gastric cancer metastasis and recurrence.

Peking University Cancer Hospital

Peking University Cancer Hospital is a large-scale modern tertiary-level Class A cancer hospital integrating medical treatment, teaching, research and prevention. It is a national key oncology discipline, a national clinical key discipline construction project, and a national clinical key specialty construction project unit for oncology and pathology. It is a leading domestic and internationally advanced unit in the diagnosis and treatment of many common tumors in China. As the leader of the group, it has participated in the formulation of diagnosis and treatment standards for gastric cancer, colorectal cancer, lung cancer, kidney cancer, melanoma, etc. It has hosted and undertaken many national key research projects and has the Ministry of Education and Beijing "Malignant Tumor Pathogenesis and Translation Research" Key Laboratory; it is the only center responsible for cancer incidence registration and survival statistics in Beijing, and provides data to the government and WHO; it is the affiliated and supporting unit of the Beijing Anti-Cancer Association and Beijing Cancer Rehabilitation Association.